Feeds:
Posts
Comments

Archive for the ‘Intellectual Property’ Category


The Digital Age Gave Rise to New Definitions – New Benchmarks were born on the World Wide Web for the Intangible Asset of Firm’s Reputation: Pay a Premium for buying e-Reputation

Curator: Aviva Lev–Ari, PhD, RN

 

Direct reputation, feedback reputation and signaling effects are present; and shows that better sellers are always more likely to brand stretch. The comparative statics with respect to the initial reputation level, however, are not obvious. … a higher reputation firm can earn a higher direct reputation effect premium. But a higher reputation firm also has more to lose. The trade-off between using one’s reputation and protecting it can go both ways.

Luıs M B Cabral, New York University and CEPR, 2005

 

 

Part 1:   A Digital Business Defined and the Intangible Asset of Firm’s Reputation

  1.  Claiming Distinction
  2.  Recognition Bestowed
  3.  The Technology
  4.  The Sphere of Influence
  5.  The Industrial Benefactors in Potential
  6.  The Actors at Play – Experts, Authors, Writers – Life Sciences & Medicine as it applies to HEALTH CARE
  7.  1st Level Connection on LinkedIn = +7,100 and Endorsements = +1,500
  8.  The DIGITAL REPUTATION of our Venture – Twitter for the Professional and for Institutions
  9.  Growth in Twitter Followers and in Global Reach: Who are the NEW Followers? they are OUR COMPETITION   and   other Media Establishments – that is the definition of Trend Setter, Opinion Leader and Source for Emulation
  10.  Business Aspects of the Brick & Mortar World render OBSOLETE

Part 2:   Business Perspectives on Reputation

Part 3:   Economics Perspectives on Reputation

 

 

Part 1:   A Digital Business Defined and the Intangible Asset of Firm’s Reputation

This curation attempts to teach-by-example the new reality of the Intangible Asset of Firm’s Reputation when the business is 100% in the cloud, 100% electronic in nature (paperless), the customers are the Global Universe and the organization is 100% Global and 100% virtual.

 

A Case in Point: Intellectual Property Production Process of Health Care Digital Content using electronic Media Channels

 

Optimal Testimonial of e-Product Quality and Reputation for an Open Access Online Scientific Journal pharmaceuticalintelligence.com 

 

 1.   Claiming Distinction

Executive Summary

WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019

 

2.   Recognition Bestowed 

Our Books are here

  • On 8/17/2018, Dr. Lev-Ari, PhD, RN was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board.

http://www.maacadsci.org

MAS FELLOWS 

GOVERNING BOARD

ACTIVITIES

BUNDLED BY AMAZON.COM INTO A SIX-VOLUME SERIES FOR $515

https://lnkd.in/e6WkMgF

Sixteen Volumes ARE ON AMAZON.COM, average book length – 2,400 pages

https://lnkd.in/ekWGNqA

3.   The Technology

Curation Methodology – Digital Communication Technology to mitigate Published Information Explosion and Obsolescence in Medicine and Life Sciences

Detailed Technology Description

LPBI’s Pipeline Map: A Positioning Perspectives – An Outlook to the Future from the Present

 

4.   The Sphere of Influence 

LPBI Group’s Social Media Presence

JOURNAL Statistics on 2/24/2019

  • LPBI Platform is been used by GLOBAL Communities of Scientists for interactive dialogue of SCIENCE – Four case studies are presented in the link, below

Electronic Scientific AGORA: Comment Exchanges by Global Scientists on Articles published in the Open Access Journal @pharmaceuticalintelligence.com – Four Case Studies

Curator and Editor-in-Chief: Journal and BioMed e-Series, Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/04/10/electronic-scientific-agora-comment-exchanges-by-global-scientists-on-articles-published-in-the-open-access-journal-pharmaceuticalintelligence-com-four-case-studies/

 

5.   The Industrial Benefactors in Potential

Opportunities Map in the Acquisition Arena

Dynamic Contents for LPBI Group’s PowerPoint Presentation

Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class 

 

6.   The Actors at Play – Experts, Authors, Writers – Life Sciences & Medicine as it applies to HEALTH CARE

Founder’s Role in the Development of Venture’s Factors of Content Production – Biographical Notes by Aviva Lev-Ari, PhD, RN, LPBI Group

Top Authors by Number of eReaders Views

Top Articles by Number of e-Readers for All Days ending 2019-02-17

FIT Members Contribute to Opportunities Map

FINAL IMPROVEMENT TEAM (FIT): Definition of Active, Lapsing of Active Status, COMPs Formulas

FIT members – Who works on WHAT?

Summer 2019 Plan – Research Associates Tasks

 

7.   1st Level Connection on LinkedIn = +7,100 and Endorsements = +1,500

Connections First Level on LinkedIn: 500 CEOs, 200 Big Pharma Professionals, 7,000 in Total: LPBI Group Founder – Aviva Lev-Ari, PhD, RN

 

8.   The DIGITAL REPUTATION of our Venture – Twitter for the Professional and for Institutions

Mostly HONORED to be followed by [from an Excerpt of 117 Followers of the Twitter Account @AVIVA1950 from the List of 359 Followers] by the Number of their Followers on 2/24/2019

LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019

Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019

Excerpt of 117 Followers of @AVIVA1950 (from the List of 359 Followers) by the Number of their Followers

REACH – Two Handles on Twitter.com @AVIVA1950 @pharma_BI

9.   Growth in Twitter Followers and in Global Reach: Who are the NEW Followers: OUR COMPETITION and other Media Establishments – that is the definition of Trend Setter, Opinion Leader and Source for Emulation

@4openjournalFollows you

Follow

4open is a multi- & inter-disciplinary, online, peer-reviewed, open access journal publishing across a broad range of subjects in the STEM domain.

@roll_clausFollows you

Follow

Publishing Editor at 

@EDPSciences

@PubtextoPFollows you

Following

Pubtexto is an International online publishing organization that publishes Scientific literature through its different open access Journals.

@alexanderlabrieFollows you

Following

CEO 

@sphereinc

@BjoernBruecherFollows you

Following

THEODOR-BILLROTH-ACADEMY® 

(link: http://linkedin.com/in/bruecher)

linkedin.com/in/bruecher // 

(link: http://4open-sciences.org)

4open-sciences.org – Editor-in-Chief // Science Profile – 

(link: http://researchgate.net/profile/Bjoern)

researchgate.net/profile/Bjoern

@MPDexpertFollows you

Follow

translate research into life-changing Global manufactured Medical Products – drugs, devices, biotech, combination; anything requiring FDA approval#MedProdDev

@P_A_MORGONFollows you

Following

Life science expert & investor_travel, wine & golf amateur_Proud father of 2 girls_My Tweets are only mine 

@INmuneBioFollows you

Follow

INmune Bio, Inc. is developing therapies that harness patient’s #immunesystem to treat #cancer. Our focus is on #NKcells and #myeloid derived suppressor cells.

@sallyeavesFollows you

Following

Innovating #tech #education #business CEO CTO Advisor & Prof. #blockchain #AI 

@OxfordSBS

@Forbes

 #FinTech #speaker #SDGs #STEM #techforgood #sustainability

@sciencetracker2Follows you

You will hear more recent and cool scientific news here. Besides, some health and tech news. Follow us in

(link: http://facebook.com/sciencetracker2)

facebook.com/sciencetracker2

13.8K Following

24.6K Followers

Followed by Stanford Tweets, Biotech Week Boston, and 23 others you follow

@sgruenwaldFollows you

Following

MD, PhD, scientist, futurist, entrepreneur, managing director of 

(link: http://www.genautica.com)

genautica.com, co-founder 

(link: http://www.diagnomics.com)

diagnomics.com

(link: http://www.scoop.it/t/amazing-science)

scoop.it/t/amazing-scie…user

 

10.  Business Aspects of the Brick & Mortar World render OBSOLETE

Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes

Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series

2013-2019, On the Medical & Scientific Bookshelf in Kindle Store: eReader Behaviors: Browsing, Page Downloads and Buying e-Books – LPBI Group’s BioMed e-Series, Royalties Payment Analysis 

 

Part 2: BUSINESS PERSPECTIVES on Reputation

 

Warren Buffett on reputation: the economic value of values, integrity and corporate culture

Warren Buffett understands that reputation and integrity have economic value. Research that shows that a good reputation is worth real money — in fact, some research indicates that a good reputation might replace a line of credit at the bank. In his book Berkshire Beyond Buffett: The Enduring Value of Values, Lawrence Cunningham argues that one of Berkshire Hathaway’s greatest assets is reputation.

https://www.finn.agency/fr/warren-buffett-reputation-berkshire-hathaway

 

The Value of Reputation

Thomas Pfeiffer1,2,4,*, Lily Tran5, Coco Krumme5 and David G Rand1,3,* 1 Program for Evolutionary Dynamics, FAS, 2 School of Applied Sciences and Engineering, and 3 Department of Psychology, Harvard University, Cambridge MA 02138, USA 4 New Zealand Institute for Advanced Study, Massey University, Auckland 0745, New Zealand 5 MIT Media Laboratory, Cambridge MA 02139, USA

 

Reputation plays a central role in human societies.

Empirical and theoretical work indicates that a good reputation is valuable in that it increases one’s expected payoff in the future. Here, we explore a game that couples a repeated Prisoner’s Dilemma (PD), in which participants can earn and can benefit from a good reputation, with a market in which reputation can be bought and sold. This game allows us to investigate how the trading of reputation affects cooperation in the PD, and how participants assess the value of having a good reputation. We find that depending on how the game is set up, trading can have a positive or a negative effect on the overall frequency of cooperation. Moreover, we show that the more valuable a good reputation is in the PD, the higher the price at which it is traded in the market. Our findings have important implications for the use of reputation systems in practice.

Keywords: evolution of cooperation; reciprocal altruism; indirect reciprocity; reputation

http://decisionlab.harvard.edu/_content/research/papers/Krumme_Pfieffer_Tran_and_Rand_Value_of_Reputation.pdf

 

The Impact of Reputation on Market Value by Simon Cole

One of the most familiar, but least understood, intangible assets is a firm’s reputation.

Simon Cole is the founding partner of the corporate reputation and branding consultancy Reputation Dividend (www. reputationdividend.com).

http://www.reputationdividend.com/files/4713/4822/1479/Reputation_Dividend_WEC_133_Cole.pdf

 

Part 3:   ECONOMICS PERSPECTIVES on Reputation

 

The Economics of Trust and Reputation: A Primer

Luıs M B Cabral New York University and CEPR, June 2005, lecture series at the University of Zurich

lcabral@stern.nyu.edu

https://pdfs.semanticscholar.org/24e5/2f3bd22d4bfa86902e5ae07d57039480004f.pdf

 

Notes on the literature

Important note: The notes in this section are essentially limited to the ideas discussed in the present version of these lectures notes. They cannot therefore be considered a survey of the literature. There are dozens of articles on the economics of reputation which I do not include here. In a future version of the text, I hope to provide a more complete set of notes on the literature. The notes below follow the order with which topics are presented.

Bootstrap models. The bootstrap mechanism for trust is based on a general result known as the folk theorem (known as such because of its uncertain origins). For a fairly general statement of the theorem (and its proof) see Fudenberg and Makin (1986). One of the main areas of application of the folk theorem has been the problem of (tacit or explicit) collusion in oligopoly. This is a typical problem of trust (or lack thereof): all firms would prefer prices to be high and output to be low; but each firm, individually, has an incentive to drop price and increase output. Friedman (1971) presents one of the earliest formal applications of the folk theorem to oligopoly collusion. He considers the case when firms set prices and history is perfectly observable. Both of the extensions presented in Section 2.2 were first developed with oligopoly collusion applications in mind. The case of trust with noisy signals (2.2.1) was first developed by Green and Porter (1984). A long series of papers have been written on this topic, including the influential work by Abreu, Pearce and Stacchetti (1990). Rotemberg and Saloner (1986) proposed a model of oligopoly collusion with fluctuating market demand. In this case, the intuition presented in Section 2.2.2 implies that firms collude on a lower price during periods of higher demand. This suggests that prices are counter-cyclical in markets where firms collude. Rotemberg and Saloner (1986) present supporting evidence from the cement industry. A number of papers have built on Rotemberg and Saloner’s analysis. Kandori (1992) shows that the i.i.d. assumption simplifies the analysis but is not crucial. Harrington (19??) considers a richer demand model and looks at how prices vary along the business cycle. The basic idea of repetition as a form of ensuring seller trustworthiness is developed in Klein and Leffler (1981). See also Telser (1980) and Shapiro (1983). When considering the problem of free entry, Klein and Leffler (1981) propose advertising as a solution, whereas Shapiro (1983) suggests low intro25 ductory prices. Section ?? is based on my own research notes. The general analysis of selfreinforcing agreements when there is an outside option of the kind considered here may be found in Ray (2002). Watson (1999, 2002) also considers models where the level of trust stars at a low level and gradually increases.

Bayesian models. The seminal contributions to the study of Bayesian models of reputation are Kreps and Wilson (1982) and Milgrom and Roberts (1982). The model in Section 3.2.1 includes elements from these papers as well as from Diamond (1989). H¨olmstrom (1982/1999) makes the point that separation leads to reduced incentives to invest in reputation. The issue of reputation with separation and changing types is treated in detail in the forthcoming book by Mailath and Samuelson (2006). In Section 3.3, I presented a series of models that deal with name as carriers of reputations. The part on changing names (Section 3.3.1) reflects elements from a variety of models, though, to the best of my knowledge, no study exists that models the process of secret, costless name changes in an infinite period adverse selection context. The study of markets for names follows the work by Tadelis (1999) and Mailath and Samuelson (2001). All of these papers are based on the Bayesian updating paradigm. Kreps (1990) presents an argument for trading reputations in a bootstrap type of model. The analysis of brand stretching (Section 3.3.3) is adapted from Cabral (2000). The paper considers a more general framework where the direct reputation, feedback reputation and signalling effects are present; and shows that better sellers are always more likely to brand stretch. The comparative statics with respect to the initial reputation level, however, are not obvious. As we saw above, a higher reputation firm can earn a higher direct reputation effect premium. But a higher reputation firm also has more to lose. The trade-off between using one’s reputation and protecting it can go both ways. For other papers on brand stretching and umbrella branding see Choi (1998), Anderson (2002).

Bibliography

Abreu, Dilip, David Pearce and Ennio Stacchetti (1990), “Toward a Theory of Discounted Repeated Games with Imperfect Monitoring,” Econometrica 58, 1041–1064. Andersson, Fredrik (2002), “Pooling reputations,” International Journal of Industrial Organization 20, 715–730. Bernhein, B. Douglas and Michael D. Whinston (1990), “Multimarket Contact and Collusive Behavior,” Rand Journal of Economics 21, 1–26. Cabral, Lu´ıs M B (2000), “Stretching Firm and Brand Reputation,” Rand Journal of Economics 31, 658-673. Choi, J.P. (1998), “Brand Extension and Informational Leverage,” Review of Economic Studies 65, 655–69. Diamond, Douglas W (1989), “Reputation Acquisition in Debt Markets,” Journal of Political Economy 97, 828–862. Ely, Jeffrey C., and Juuso Valim ¨ aki ¨ (2003), “Bad Reputation,” The Quarterly Journal of Economics 118, 785–814. Fishman, A., and R. Rob (2005), “Is Bigger Better? Customer Base Expansion through Word of Mouth Reputation,” forthcoming in Journal of Political Economy. Friedman, James (1971), “A Noncooperative Equilibrium for Supergames,” Review of Economic Studies 28, 1–12. Fudenberg, Drew and Eric Maskin (1986), “The Folk Theorem in Repeated Games with Discounting or with Imperfect Public Information,” Econometrica 54, 533–556. Green, Ed and Robert Porter (1984), “Noncooperative Collusion Under Imperfect Price Information,” Econometrica 52, 87–100. Holmstrom, Bengt ¨ (1999), “Managerial Incentive Problems: A Dynamic Perspective,” Review of Economic Studies 66, 169–182. (Originally (1982) in Essays in Honor of Professor Lars Wahlback.) Kandori, Michihiro (1992), “Repeated Games Played by Overlapping Generations of Players,” Review of Economic Studies 59, 81–92. Klein, B, and K Leffler (1981), “The Role of Market Forces in Assuring Contractual Performance,” Journal of Political Economy 89, 615–641. 27 Kreps, David (1990), “Corporate Culture and Economic Theory,” in J Alt and K Shepsle (Eds), Perspectives on Positive Political Economy, Cambridge: Cambridge University Press, 90–143. Kreps, David M., Paul Milgrom, John Roberts and Robert Wilson (1982), “Rational Cooperation in the Finitely Repeated Prisoners’ Dilemma,” Journal of Economic Theory 27, 245–252. Kreps, David M., and Robert Wilson (1982), “Reputation and Imperfect Information,” Journal of Economic Theory 27, 253–279. Mailath, George J, and Larry Samuelson (2001), “Who Wants a Good Reputation?,” Review of Economic Studies 68, 415–441. Mailath, George J, and Larry Samuelson (1998), “Your Reputation Is Who You’re Not, Not Who You’d Like To Be,” University of Pennsylvania and University of Wisconsin. Mailath, George J, and Larry Samuelson (2006), Repeated Games and Reputations: Long-Run Relationships, Oxford: Oxford University Press. Milgrom, Paul, and John Roberts (1982), “Predation, Reputation, and Entry Deterrence,” Journal of Economic Theory 27, 280–312. Phelan, Christopher (2001), “Public Trust and Government Betrayal,” forthcoming in Journal of Economic Theory. Ray, Debraj (2002), “The Time Structure of Self-Enforcing Agreements,” Econometrica 70, 547–582. Rotemberg, Julio, and Garth Saloner (1986), “A Supergame-Theoretic Model of Price Wars During Booms,” American Economic Review 76, 390–407. Shapiro, Carl (1983), “Premiums for High Quality Products as Rents to Reputation,” Quarterly Journal of Economics 98, 659–680. Tadelis, S. (1999), “What’s in a Name? Reputation as a Tradeable Asset,” American Economic Review 89, 548–563. Tadelis, Steven (2002), “The Market for Reputations as an Incentive Mechanism,” Journal of Political Economy 92, 854–882. Telser, L G (1980), “A Theory of Self-enforcing Agreements,” Journal of Business 53, 27–44. Tirole, Jean (1996), “A Theory of Collective Reputations (with applications to the persistence of corruption and to firm quality),” Review of Economic Studies 63, 1–22. 28 Watson, Joel (1999), “Starting Small and Renegotiation,” Journal of Economic Theory 85, 52–90. Watson, Joel (2002), “Starting Small and Commitment,” Games and Economic Behavior 38, 176–199. Wernerfelt, Birger (1988), “Umbrella Branding as a Signal of New Product Quality: An Example of Signalling by Posting a Bond,” Rand Journal of Economics 19, 458–466.

https://pdfs.semanticscholar.org/24e5/2f3bd22d4bfa86902e5ae07d57039480004f.pdf

 

Read Full Post »


Selection Process for Chief Innovation and Entrepreneurship Officer (CIEO) @Berkeley: Ecosystem Evangelist, Professor Richard Lyons, Berkeley’s ex-Dean of the Haas School of Business

 

Reporter: Aviva Lev-Ari, PhD, RN, Berkeley PhD’83

 

for @Berkeley Alumna Ecosystem Evangelist see

https://pharmaceuticalintelligence.com/2019-vista/executive-summary/

The University of California at Berkeley appointed professor Richard Lyons as the university’s first-ever chief innovation and entrepreneurship officer (CIEO).

The Selection Process

Professor Richard Lyons was selected for the CIEO position through a rigorous recruitment and selection process that attracted several hundred top-notch applications from all over the world. Throughout the process, Lyons stood out as a true visionary, a strategic leader and an ecosystem evangelist who could understand and activate the untapped potential of Berkeley’s innovation and entrepreneurship landscape.

 

“If together we can improve the transformation of Berkeley’s prodigious intellectual product, across the whole campus, into greater societal benefit, then we will have achieved a great deal,” said Lyons, in a statement.

Image Source: Courtesy of University of California, Berkeley, Doe Library Building with the  Campanile Tower in the background

Professor Richard Lyons,  Accomplishments as Berkeley’s ex-Dean of the Haas School of Business

  • He helped launch the Management, Entrepreneurship, & Technology (M.E.T.) dual-degree program in partnership with the College of Engineering.
  • He also initiated the Biology + Business dual degree program with Molecular & Cell Biology and
  • He revitalized the Berkeley-Haas Entrepreneurship Program (BHEP).
  • He helped the campus to launch the Berkeley SkyDeck startup accelerator in 2012 and served on its Governing Board, did that in collaboration with leadership in the Office of Research and College of Engineering.

 

SOURCE

https://venturebeat-com.cdn.ampproject.org/c/s/venturebeat.com/2019/07/10/richard-lyons-will-be-uc-berkeleys-first-ever-chief-innovation-and-entrepreneurship-officer/amp/

Read Full Post »


In-House Development of an intellectual property value calculator (IP-V-Cal) for Valuation of INTANGIBLE products: Intellectual property (IP) assets of Digital Printed Products (DPP) – Online Journal(s), e-Books and a Corpus of Real Time generated eProceedings of the Top Biotech Global Conferences

Author: Aviva Lev-Ari, PhD, RN

1. All the points I made, below in my e-mail 4AM on 6/28/2019, see below – to match Intangible Assets in Document #2, 4/19/2019 in Inbox of each FIT member.

(after reading Rick’s article we received a link to and after reading the link that I provided in this e-mail)

2. We Need Amnon to enter into an Excel spread sheet as Column #1 all the Contributing Factors to valuation in that 4AM e-mail

3. Columns #2,#3,#4 will be Gail, Amnon, Rick (Business Team)

4. Columns #5,#6 will be Dr. Williams, Prof. Feldman (our Board)

5. Columns #7,#8 #9,#10 will be Dr. Pearlman, Dr. Dror Nir, Dr. Saha, Dr. Irina (Scientists Team)

7. Each Column dedicated to each of out 10 alive and well Active FIT

Will be split into two columns

6. Column #11 will be Aviva’s 

8. First column of each of the 10 FIT members will be filled by each by a number between 50 to 100, representing the subjectively perceived contributing weight of the Factor mentioned in Column 1: list of factors contributing to Venture’s valuation

9. Second column of each of the 10 FIT members will list the member’s subjective perspective on Ranking the Factors in Column #1

10. To Column #1: each Business Team member (mentioned in 3, above), needs to contribute FIVE new factors taken from your discussion on Valuation add them with your initials to Column #1

11. Aviva will bring DATA from Article Scoring System already populating a database designed to quantify the 

11.1 Valuation of the Journal

11.2 Valuation of the BioMed e-Series: each book, each series, all 16 volumes

11.3 Author’s factor in pricing 11.1 and 11.2

 

12. Valuation of 70 eProceedings 

(60 by Aviva; 10 by Dr. Williams)

needs to be tied to a growth factor in LPBI Group’s INFLUENCE on Twitter

12.1 @pharma_BI

12.2 @AVIVA1950

12.3 Gail’s Twitter account

12.4 Dr. Williams’ Twitter account

12.5 Dr. Asha’s Twitter account

12.6 Dr. Irina’s Twitter account

Factors of INFLUENCE:

– Growth in #Followers on Twitter 

– Ratio #Tweets/#Likes

– Cumulative # of Followers’ Followers

13. LinkedIn

I discovered new features and I wish to conduct a Skype training session with narrow messaging to FIT members

Please contribute your thoughts, while 

 

– Amnon is building this Excel

– Irina will be designing DropBox for this Excel that TEN FIT members need to add a number 50 to 100, Ranking the relative importance of each factor for Venture Valuation

GREAT initiative by Business Team to focus on valuation, thank you.

Thank you all FIT members, get ready yo add your subjective numbers into the Valuation Excel.

Amnon, please share with me in a Skype session the draft of this Excel, before we deplore this instrument, place it in Dropbox and announce the window of one week when we collect 2×10 data points on each of the Factors in Column #1, 

Board members and Scientists: you are welcome to contribute Factors in Valuation of the Venture in Column #1, the longer this column, the greater the granularity. 

We can then focus only on factors that scored above the Mean or any cut off point we will agree upon.

Thank you all – it is exciting to get the entire Team, developing a custom tailor methodology for DIGITAL printed products, NO OFF THE SHELF MODEL WILL FIT US. 

Current valuation models that do NOT APPLY to our venture include the following:

“Book to market value” 

– we got Intangibles, Column #1

– LPBI Group’s Tangibles are royalties for books sold. 

(all data was reviewed by Dr. Williams, for Section #13 in Document #2, for the period, 4/2012 to 4/19/2019)

“VC investment dilution models” 

– we kept 100% of ownership 

– our shareholders are 12 FIT members: 

— >>>>>> 10 are active members 

– (Scientist Team: Formula in place) (Gail included)

– (Business Team: 10% of UPSIDE) (Gail included)

— >>>>>> Past commitments outstanding:

– to Dr. Larry and 

– to Adam Sonnenberg

– (Formula in place). 

– No UPSIDE, due to idle status since 2/6/2019, Exit period launch.

Thank you again.

Aviva Lev-Ari, PhD, RN

Editor-in-Chief, BioMed e-Series

http://PharmaceuticalIntelligence.com

Director & Founder

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

On Jun 28, 2019, at 3:57 AM, Amnon Danzig <amnon.danzig@gmail.com> wrote:

This is a nice article that put in place Corporate Finance practices.

However, The Business Team currently is struggling in much more earlier stages of the valuation of the Group.

We have a long way to go before we are entering the valuation scene in numeric terms.

Aviva,

I must confess that in the last two weeks we (Rick, Gail and me) invested huge amount of work to disclose the real valuation of the Group.

It is a work-in-process.

Thank you for your patience.

Amnon

Amnon Danzig

Business Strategy 

https://lnkd.in/e-zTVz4

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Israel

http://pharmaceuticalintelligence.com 

e-Mailamnon.danzig@gmail.com

(M) +972-54-6998405

 www.amnondanzig.com

SkypeID: Amnon.Danzig  LinkedIn Profile Twitter Profile

On Fri, Jun 28, 2019 at 10:30 AM Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

What is Aviva’s take on LPBI Group Valuation?

https://bothsidesofthetable.com/do-you-really-even-need-vc-72013e985fab

  • Advantages of LPBI Group:
  1. We had low barrier to entry and 
  2. We had/have Zero labor cost
  3. We are virtual, therefore, no overhead expenses 
  4. Run rate at WordPress.com Business Premium Annual Fee $200 and LinkedIn Annual Business Premium $1000
  5. Our 1st CARDINAL factor of production [The Team] is the DEAPTH and very diverse EXPERTISE residing in the Scientist Team and in the Business TEAM
  6. Leadership expressed by new timely challenge selection – Directions into new domains
  7. Team ability to swarm around new domains (new timely challenge selection), Examples: 
  • 2015-2016 – 3D BioPrinting – Book: Series E, Volume 4
  • Volume 4: Medical 3D BioPrinting – The Revolution in Medicine, Technologies for Patient-centered Medicine: From R&D in Biologics to New Medical Devices. On Amazon.com since since 12/30/2017

https://www.amazon.com/dp/B078QVDV2W

  • 2016-2017 – Drug Discovery – JV with SBH Sciences, Dr. Raphael Nir

https://pharmaceuticalintelligence.com/drugdiscovery-lpbi-group/

  • 2019-2020 – AI + ML in Medicine – Book: Series B, Volume 2

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

  1. Our 2nd CARDINAL factor of Leadership is the FIDELITY of a CORE team of Scientists
  2. Aviva’s ability to multitask on several levels – FIVE persons in just One woman (nee: 1950): 
  • LPBI Group’s DAILY activity on Twitter, LinkedIn, Facebook
  • IN PERSON at +60 Conferences – yielded a Corpus of eProceedings N=70 [10 by Dr. Williams 
  • Curator of new content – Journal is LIVE at 

1,639,029 eReaders 

Content

5,642

Posts

686

Categories

10,083

Tags

  • Book Editor – multiple domains of knowledge: Series A, B, D, E
  • Full functions of Editor-in-Chief: 16 Titles, content acquisition, eTOCs designer
  • Relations builder with multiple Ecosystems: Israel, US, Europe – stay tune

4/19/2019 

@pharma_Bi # Followers = 505 

6/28/2019

@pharma_Bi # Followers = 519 RatioTweets to Likes: 25,000/3,086

4/19/2019 

@AVIVA1950 # Followers = 359

6/28/2019

@AVIVA1950 # Followers = 439 RatioTweets to Likes: 11,000/5,615

How can you use all of the above for your Valuation Modeling???

Read Full Post »


Pfizer buys out Array BioPharma for $11.4 Billion to beef up its oncology offerings

Reporter: Stephen J. Williams, PhD

As reported in FiercePharma.com:

by Angus Liu |

Three years after purchasing Medivation for $14.3 billion, Pfizer is back with another hefty M&A deal. And once again, it’s betting on oncology.

In the first big M&A deal under new CEO Albert Bourla, Pfizer has agreed to buy oncology specialist Array BioPharma for a total value of about $11.4 billion, the two companies unveiled Monday. The $48-per-share offer represents a premium of about 62% to Array stock’s closing price on Friday.

With the acquisition, Pfizer will beef up its oncology offerings with two marketed drugs, MEK inhibitor Mektovi and BRAF inhibitor Braftovi, which are approved as a combo treatment for melanoma and recently turned up positive results in colon cancer.

The buy will enhance the Pfizer innovative drug business’ “long-term growth trajectory,” Bourla said in a Monday statement, dubbing Mektovi-Braftovi “a potentially industry-leading franchise for colorectal cancer.”

RELATED: Array’s ‘extremely compelling’ new colon cancer data spark blockbuster talk

In a recent interim analysis of a trial in BRAF-mutant metastatic colorectal cancer, the pair, used in tandem with Eli Lilly and Merck KGaA’s Erbitux, produced a benefit in 26% of patients, versus the 2% that chemotherapy helped. The combo also showed it could reduce the risk of death by 48%. SVB Leerink analysts at that time called the data “extremely compelling.”

Right now, one in every three new patients with mutated metastatic melanoma is getting the combo, despite its third-to-market behind combos from Roche and Novartis, Andy Schmeltz, Pfizer’s oncology global president, said during an investor briefing on Monday.

It is being studied in more than 30 clinical studies across several solid tumor indications. Moving forward, Pfizer believes the combo could potentially be used in the adjuvant setting to prevent tumor recurrence after surgery, Pfizer’s chief scientific officer, Mikael Dolsten, said on the call. The company is also keen to know how it could be paired up with Pfizer’s own investigational PD-1, he said, as the combo is already in studies with other PD-1/L1s.

But as Pfizer execs have previously said, the company’s current business development strategy no longer centers on adding revenues “now or soon,” but rather on strengthening Pfizer’s pipeline with earlier-stage assets. And Array can help there, too.

“We are very excited by Array’s impressive track record of successfully discovering and developing innovative small-molecules and targeted cancer therapies,” Dolsten said in a statement.

On top of Mektovi and Braftovi, Array has a long list of out-licensed drugs that could generate big royalties over time. For example, Vitrakvi, the first drug to get an initial FDA approval in tumors with a particular molecular feature regardless of their location, was initially licensed to Loxo Oncology—which was itself snapped up by Eli Lilly for $8 billion—but was taken over by pipeline-hungry Bayer. There are other drugs licensed to the likes of AstraZeneca, Roche, Celgene, Ono Pharmaceutical and Seattle Genetics, among others.

Those drugs are also a manifestation of Array’s strong research capabilities. To keep those Array scientists doing what they do best, Pfizer is keeping a 100-person team in Colorado as a standalone research unit alongside Pfizer’s existing hubs, Schmeltz said.

Pfizer is counting on Array to augment its leadership in breast cancer, an area championed by Ibrance, and prostate cancer, the pharma giant markets Astellas-partnered Xtandi. For 2018, revenues from the Pfizer oncology portfolio jumped to $7.20 billion—up from $6.06 billion in 2017—mainly thanks to those two drugs.

Source: https://www.fiercepharma.com/pharma/pfizer-never-say-never-m-a-buys-oncology-innovator-array-for-11-4b

 

About Array BioPharma

Array markets BRAFTOVI® (encorafenib) capsules in combination with MEKTOVI® (binimetinib)  tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K  mutation in the United States and with partners in other major worldwide markets.* Array’s lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant metastatic colorectal cancer. Array’s pipeline includes several additional programs being advanced by Array or current license-holders, including the following programs currently in registration trials: selumetinib (partnered with AstraZeneca), LOXO-292 (partnered with Eli Lilly), ipatasertib (partnered with Genentech), tucatinib (partnered with Seattle Genetics) and ARRY-797. Vitrakvi® (larotrectinib, partnered with Bayer AG) is approved in the United States and Ganovo® (danoprevir, partnered with Roche) is approved in China.

 

Other Articles of Note of Pfizer Merger and Acquisition deals on this Open Access Journal Include:

From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma

Pfizer Near Allergan Buyout Deal But Will Fed Allow It?

Pfizer offers legal guarantees over AstraZeneca bid

Re-Creation of the Big Pharma Model via Transformational Deals for Accelerating Innovations: Licensing vs In-house inventions

Read Full Post »


Real Time Coverage @BIOConvention #BIO2019: Keynote Address Jamie Dimon CEO @jpmorgan June 5 Philadelphia

Reporter: Stephen J. Williams, PhD @StephenJWillia2

 

  • Dr Janet Woodcock from FDA was given the BIO Heritage award for leading the FDA from safety focus of 90s to the Voice of the Patient. She became a champion for advocacy groups
  • Governor Phil Murphy, Governor of New Jersey, received the Governor of the Year Award.  New Jersey known as medicine chest of the world, have first 3D printed drug on market and number two in biotech and number one on drug approvals.  We must do more to foster stem education.  It will take private and public capital investment.  New Jersey matches federal dollars and had doubled the angel investor tax credit.
  • Dr. Kakkis CEO of Ultragenix wins the Genzyme Henri Termeer Award for visionary work.  Dr. Termeer recently passed.  Dr. Kakkis is awarded for work with patients of rare diseases and help formulating legislation to help patients with rare disease have access to investigational drugs quickly.
  • Dr. Jeremy Levin from OVID named new chair of BIO

Interview with Jamie Dimon, CEO of JPMorgan

  • Mr Dimon had recently survived throat cancer and now has a renewed dedication to improving people’s lives.  With Amazon had embarked on a nonprofit experimental model to streamline healthcare for their employees.  He said the hardest part of going through cancer was telling his parents and children.
  • On the bailout he said it was a lie all banks needed TARP but could not just give to some and not all.  He says the financial system in US is very solid so next downturn will not come from financial sector and never is from geopolitical but trade issues could be a catalyst. Policy usually always does the opposite of what is intended.  He announced no intention of running for President of US.
  • We need to keep a growth agenda which includes education and infrastructure, without these competitive business tax relief does no account for much.  We need a better conversation of how government handles finances
  • Immigration, education very important.  Higher education needs to reduce costs and incentivize the people they bring in to stay here.
  • on healthcare:  JPM had reduced the deductables to zero for workers making $60,000 or less

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Other Article on this Open Access Journal on Global Partnerships, Global Investing and JPMorgan Include:

 

Read Full Post »


At California Central District Court Juno Therapeutics, Inc. et al v. Kite Pharma, Inc. – Multi-party Patent Infringement

Curator and Reporter: Aviva Lev-Ari, PhD, RN

 

Infringement of Patent: US7446190B2 – which is exclusively licensed to Juno Therapeutics, Inc.

United States

Inventor
Michel Sadelain
Renier Brentjens
John Maher
Current Assignee
Sloan-Kettering Institute for Cancer Research

Worldwide applications
2003  US

Application US10/448,256 events
2002-05-28
Priority to US38387202P
2008-11-04
Application granted
Application status is Active
Adjusted expiration
Show all events

 

SUMMARY OF INVENTION

The present invention provides chimeric TCR’s, nucleic acid polymer encoding the chimeric TCR’s and methods of using the chimeric TCR’s to facilitate T cell response to a specific target. The chimeric TCR’s of the invention combine, in a single chimeric species, the intracellular domain of CD3 ζ-chain (“zeta chain portion”), a signaling region from a costimulatory protein such as CD28 and a binding element that specifically interacts with a selected target. Thus, in accordance with a first aspect of the invention, there is provided a nucleic acid encoding a chimeric T cell receptor, said chimeric T cell receptor comprising a zeta chain, a CD28 signaling region and a binding element that specifically interacts with a selected target. In accordance with a second aspect of the invention, there is provided a chimeric T cell receptor comprising a zeta chain portion, a CD28 signaling region and a binding element.

In accordance with the method of the invention a chimeric TCR is provided which comprises a zeta chain portion, a co-stimulatory signaling element and a binding element which specifically interacts with a cellular marker associated with target cells. T-lymphocytes from the individual to be treated, for example a human individual, are transduced with the chimeric TCR. This transduction may occur ex vivo, after which the transduced cells are reintroduced into the individual. As a result, T cell immune response is stimulated in the individual to the target cells.

SOURCE

https://patents.google.com/patent/US7446190B2/en

  • Prior Art Search results: (cells) (nucleic acid) (acid polymer) (cell) (cd28) before:priority:2002-05-28

Assignees Inventors include:

C12P21
C12P21/00
C12P
C12P21/02
C07K14/52
C07K14/715
C07K14/54
C07K14/521
C07K14/47
C07K14/46
C12N9/6432
C12Y304/21006
C07K14/47
C07K14/46
C07K14/475
C07K14/435
A01K2217
A01K2217/00
A01K
A01K2217/075
C12N2533/00
C12N2533/14
C12N2533/18
C12N2533/30
G01N33/502
G01N33/5041
Y10S435/973
G01N33/5008
B01J2219/00648
B01J2219/00306
B82Y15/00
B01J2219/00646
C07K14/70532
C07K14/70503
C07K16/2827
A61K2039/5158
A61K38/1774
A61K31/33
A61K45
A61K45/06
C07K14/70532
C12N2795
C12N2795/00
C12N2795/00011
C07K14/47
C07K14/46
A61K48/00
C07K14/435
C12N2510/00
C12N2502/99
C12N2501/515
C12N2501/51
C07K14/70503
A61K38/00
A61K
C07K14/705
G01N33/6878
G01N33/68
C07K1/047
C07K1/04
C07K14/70503
A01K2217/05
C07K14/705
A01K2217
Y02A50/38
A61K2039/6068
A61K2039/6025
C07K2319/21
C07K14/47
C07K14/46
A61K48/00
C07K14/435
C07K14/4747
C07K14/70575
A61K45/06
A61K45

SOURCE

https://patents.google.com/?q=cells&q=nucleic+acid&q=acid+polymer&q=cell&q=cd28&before=priority:20020528&scholar

 

IRELL & MANELLA LLP Morgan Chu (SBN 70446) Alan J. Heinrich (SBN 212782) Elizabeth C. Tuan (SBN 295020) 1800 Avenue of the Stars, Suite 900 Los Angeles, California 90067-4276 Telephone: (310) 277-1010 Facsimile: (310) 203-7199 Attorneys for

Plaintiffs JUNO THERAPEUTICS, INC., MEMORIAL SLOAN KETTERING CANCER CENTER, and SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF CALIFORNIA Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, and Sloan Kettering Institute for Cancer Research,,

Plaintiffs, v. Kite Pharma, Inc., Defendant. ) ) ) ) ) ) ) ) ) ) ) )

CASE NO.: 2:17-CV-07639

COMPLAINT FOR PATENT INFRINGEMENT

DEMAND FOR JURY TRIAL

Case 2:17-cv-07639 Document 1 Filed 10/18/17 Page 1 of 14 Page ID #:1

Knowing that it infringes the ’190 Patent, Kite challenged the validity of all claims of the ’190 Patent in an inter partes review (“IPR”) in the United States Patent and Trademark Office (“PTO” or “Office”) before the Patent Trial and Appeal Board (“PTAB” or “Board”). The PTAB instituted the IPR and then upheld all claims of the ’190 Patent in a Final Written Decision issued December 16, 2016. The PTAB concluded that Kite did not even show “by a preponderance of the evidence”—the lower standard applicable to validity challenges in an IPR—that any claim of the ’190 Patent was unpatentable.

Kite recently received marketing approval from the Food and Drug Administration (“FDA”) for its Yescarta™ product (axicabtagene ciloleucel) (“axicel” or “Yescarta,” also known as “KTE-C19”) on October 18, 2017. Plaintiffs accordingly bring suit against Kite for infringement based on Kite’s making, using, offering to sell, and selling of its chimeric antigen receptor products that comprise the claimed nucleic acid polymers of the ’190 Patent. 35 U.S.C. § 271(a). Plaintiffs hereby allege for their Complaint against Defendant Kite, on personal knowledge as to their own actions and on information and belief as to the actions of others,

26. Indeed, the DNA sequence of Kite’s retroviral vector demonstrates that Kite’s anti-CD19 chimeric TCR falls within the scope of the ’190 Patent claims. In a document Kite filed with the Recombinant DNA Advisory Committee (“RAC”), a federal committee that reviews clinical trial protocols that are either directly funded by the National Institutes of Health (“NIH”) or conducted at institutions that receive NIH funding, Kite provided the DNA sequence of KTE-C19’s anti-CD19 chimeric TCR vector. Exhibit 10 (KTE-C19 DNA Sequence). The RAC filing described the retroviral vector used as

encoding a chimeric antigen receptor directed against the B cell antigen, CD19 . . . The retroviral vector utilizes the MSGV1 (murine stem cell virus-based splice-gag vector 1) retroviral vector backbone and consists of 7026 bps including the 5’ long terminal repeat (LTR) from the murine stem cell virus (promoter), packaging signal including the splicing donor (SD) and splicing acceptor sites, FMC63- based (anti-CD19 FMC63-28) CAR protein containing a signal peptide (human GM-CSF receptor), FMC63 light chain variable region (FMC63 VL), linker peptide, FMC63 heavy chain variable region (FMC63 VH), CD28 (hinge, transmembrane and cytoplasmic region), and TCR-zeta (cytoplasmic region), followed by the murine stem cell virus 3’LTR. This particular vector was provided by Dr. Steven A. Rosenberg from the Surgery Branch/NCI and is the same vector used in an ongoing RAC-approved clinical trial of which Dr. Stephen A. Rosenberg is the Principal Investigator (OBA/RAC submission 0809-940). . . . [T]he complete nucleotide sequence as determined by the standard nucleotide sequencing protocol is shown in Appendix 2 of this application.

27. During the IPR Kite initiated against the ’190 Patent, Sloan Kettering’s expert, Prof. Thomas Brocker, the Director of the Institute for Immunology at the Ludwig-Maximilians University in Munich, Germany, compared the chimeric TCR used by Kite’s scientific collaborators to the claims of the ’190 Patent, demonstrating that Kite’s collaborators’ chimeric TCR construct, and thus, Kite’s own KTE-C19 product, falls within the scope of at least claims 1-3 and 5 of the ’190 Patent. Exhibit 12 (Brocker Declaration), ¶ 224. The NCI chimeric TCR analyzed by Prof. Brocker contains the same nucleotide sequence as KTE-C19’s chimeric TCR. See Exhibit 11 (RAC Filing).

28. On October 18, 2017, Kite received approval for the FDA to market and sell Yescarta (axicabtagene ciloleucel) in the United States.

COUNT 1:

INFRINGEMENT OF THE ’190 PATENT UNDER 35 U.S.C. § 271(a)

29. Plaintiffs re-allege and incorporate by reference the allegations contained in paragraphs 1-28 above.

30. to 40. are Plaintiffs’ description of Defendant Infringement on claims of the Patent

MAIN SOURCE for Filings by Plaintiffs

http://litigationtools.maxval-ip.com/UnifiedPatentViewDocument/home/index?caseid=128416

 

 

Plaintiffs:

  • Juno Therapeutics, Inc.,
  • Memorial Sloan Kettering Cancer Center,
  • Sloan Kettering Institute for Cancer Research

Defendant and Counterclaimant

  • Kite Pharma, Inc.

 

Effective April 17, 2018, Magistrate Judge Rozella A. Oliver will be located at the Edward R. Roybal Federal Building and U.S. Courthouse, COURTROOM 590 on the 5th floor, located at 255 East Temple Street, Los Angeles, California 90012. All Court appearances shall be made in Courtroom 590 of the Roybal Federal Building,

100

Oct 9, 2018

MINUTE IN CHAMBERS CLAIM CONSTRUCTION ORDER by Judge S. James Otero: The Court finds that a POSITA encountering the 190 Patent prior to the CoC would have understood SEQ ID NO:6 to begin with nucleotide 336 of the CD28 protein. The Court construes the disputed claim terms as follows: 1. The amino acid sequence encoded by SEQ ID NO:6 before the Certificate of Correction means Amino Acids 113-220 of CD28 (starting with lysine (K)) and after the Certificate of Correction means Amino Acids 114-220 of CD28 (starting with isoleucine (I)). 2. nucleic acid polymer encoding… a binding element that specifically interacts with a selected target is given its plain and ordinary meaning. (shb) (Entered: 10/10/2018)

 

Main Doc

 

Juno Therapeutics, Inc. et al v. Kite Pharma, Inc. (2:17-cv-07639), California Central District Court

California Central District Court
Judge: S James Otero
Referred: Jacqueline Chooljian
Case #: 2:17-cv-07639
Nature of Suit 830 Property Rights – Patent
Cause 35:271 Patent Infringement
Case Filed: Oct 18, 2017
Docket last updated: 03/08/2019 11:59 PM PST 

Thursday, March 07, 2019
150 order For Order Thu 12:50 PM 
ORDER GRANTING DEFENDANT KITE PHARMA, INC.S EX PARTE APPLICATION FOR AN EXTENSION OF TIME FOR THE MAGISTRATE JUDGE TO HEAR MOTIONS TO COMPEL PRODUCTION OF DOCUMENTS AND WITNESSES144 by Judge S. James Otero: 1. Time is extended until April 17, 2019, for the Magistrate Judge to hear (a) any motions to compel Plaintiffs to produce documents that Kite has already identified as deficient in Plaintiffs production and Plaintiffs have not yet produced, and (b) a motion to compel Bristol-Myers Squibb Company to produce documents in response to Kites subpoena; and 2. Time is extended until May 10, 2019, for the Magistrate Judge to hear a motion to compel deposition testimony regarding the documents described in paragraph 1 above. (lc) Modified on 3/7/2019 (lc)
Wednesday, March 06, 2019
149 transcript -Transcript Order Form (G-120) Wed 2:56 PM 
TRANSCRIPT ORDER as to Defendant Kite Pharma, Inc. for Court Smart (CS). Court will contact Adam R. Lawton at adam.lawton@mto.com with further instructions regarding this order. Transcript preparation will not begin until payment has been satisfied with the transcription company. (Lawton, Adam)
Tuesday, March 05, 2019
147 respm Reply (Motion related) Tue 5:31 PM 
REPLY in support of EX PARTE APPLICATION for Order for Extension of Time for the Magistrate Judge to Hear Motions to Compel Production of Documents and Witnesses 144 filed by Defendant Kite Pharma, Inc..(Lawton, Adam)
Att: 1 Reply Declaration of Adam R. Lawton
146 respm Objection/Opposition (Motion related) Tue 12:26 PM 
OPPOSITION Ex Parte Application re: EX PARTE APPLICATION for Order for Extension of Time for the Magistrate Judge to Hear Motions to Compel Production of Documents and Witnesses 144Opposition filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research.(Wells, Crawford)
Att: 1 Declaration,
Att: 2 Exhibit 1
Monday, March 04, 2019
148 minutes Telephone Conference For Order re Discovery Matter Wed 9:27 AM 
MINUTES OF CONTINUED PRE-MOTION TELEPHONIC DISCOVERY CONFERENCE settling139 Motion re: Informal Discovery Dispute held before Magistrate Judge Karen L. Stevenson. Should Judge Otero grant Kite’s Ex Parte Application, Kite may file a motion to compel. In the interim, at the request of counsel for non-party BMS, who does not receive the CM/ECF notifications in this case, the Court ORDERS Defendant Kite, to provide copies to BMS counsel of the following: (1) Minutes of Pre-Motion Telephonic Discovery Conference held on February 26, 2019, (Dkt. No. 138) (see document for further details). Court Recorder: XTR 03-04-19. (hr)
145 respm Declaration (Motion related) Mon 12:52 PM 
DECLARATION of Adam R. Lawton (Corrected) in support of EX PARTE APPLICATION for Order for Extension of Time for the Magistrate Judge to Hear Motions to Compel Production of Documents and Witnesses 144 filed by Defendant Kite Pharma, Inc.. (Lawton, Adam)
144 17 pgs motion Order Mon 11:50 AM 
EX PARTE APPLICATION for Order for Extension of Time for the Magistrate Judge to Hear Motions to Compel Production of Documents and Witnesses filed by Defendant Kite Pharma, Inc.. (Lawton, Adam)
Att: 1 Proposed Order,
Att: 2 Declaration of Adam R. Lawton,
Att: 3 Exhibit 1,
Att: 4 Exhibit 2,
Att: 5 Exhibit 3,
Att: 6 Exhibit 4,
Att: 7 Exhibit 5,
Att: 8 Exhibit 6,
Att: 9 Exhibit 7,
Att: 10 Exhibit 8,
Att: 11 Exhibit 9,
Att: 12 Exhibit 10,
Att: 13 Exhibit 11,
Att: 14 Exhibit 12,
Att: 15 Exhibit 13,
Att: 16 Exhibit 14,
Att: 17 Exhibit 15,
Att: 18 Exhibit 16
Thursday, February 28, 2019
143 order Leave to File Excess Pages Thu 10:50 AM 
ORDER GRANTING-IN-PART DEFENDANT KITE PHARMA, INC.’S APPLICATION FOR LEAVE TO FILE A 10-PAGE REPLY BRIEF IN SUPPORT OF MOTION FOR SUMMARY JUDGMENT OF NONINFRINGEMENT140 by Judge S. James Otero. It is hereby ordered that Defendant Kite Pharma, Inc. may file a reply brief of no more than 10 pages in support of its motion for summary judgment of noninfringement. Plaintiffs are permitted to file a sur-reply, not to exceed 7 pages, addressing the admissibility of the expert declarations submitted in support of its opposition to Defendant’s motion for summary judgment of noninfringement. The sur-reply shall be filed no later than 5 days from Defendant’s reply. IT IS SO ORDERED. (lom)

Juno Therapeutics, Inc. v. Kite Pharma, Inc. (2:17-cv-07639)

District Court, C.D. California

 

 

 

 

 

 

 

Recorded here ONLY if PDF is Downloadable

Oct 18, 2017

COMPLAINT Receipt No: 0973-20685642 – Fee: $400, filed by Plaintiffs Juno Therapeutics, Inc., Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14) (Attorney Morgan Chu added to party Juno Therapeutics, Inc.(pty:pla), Attorney Morgan Chu added to party Memorial Sloan Kettering Cancer Center(pty:pla), Attorney Morgan Chu added to party Sloan Kettering Institute for Cancer Research(pty:pla))(Chu, Morgan) (Entered: 10/18/2017)

Main Doc

3

Oct 18, 2017

Request for Clerk to Issue Summons on Complaint (Attorney Civil Case Opening),, 1 filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research. (Chu, Morgan) (Entered: 10/18/2017)

SKIPPED

46

Jan 29, 2018

JOINT REPORT Rule 26(f) Discovery Plan ; estimated length of trial 5-12 days, filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research.. (Attachments: # 1 Appendix 2)(Chu, Morgan) (Entered: 01/29/2018)

SKIPPED

66

Mar 29, 2018

AMENDED ANSWER and AMENDED COUNTERCLAIM to Complaint (Attorney Civil Case Opening),, 1 filed by Defendant and Counterclaimant Kite Pharma, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Appendix (redline version of amended pleading))(Lawton, Adam) (Entered: 03/29/2018)

SKIPPED

74

May 11, 2018

STIPULATION for Protective Order filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research. (Attachments: # 1 Proposed Order)(Tuan, Elizabeth) (Entered: 05/11/2018)

75

May 14, 2018

ORDER GRANTING PROTECTIVE ORDER by Magistrate Judge Rozella A. Oliver re Stipulation for Protective Order 74 (dml) (Entered: 05/14/2018)

Protective Order

SKIPPED

85

Aug 13, 2018

DECLARATION of Alan J. Heinrich re Brief (non-motion non-appeal), 84 ISO Juno’s Claim Construction Brief filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research, Counter Defendants Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research. (Attachments: # 1 Exhibit Exhibit 1, # 2 Exhibit Exhibit 2, # 3 Exhibit Exhibit 3, # 4 Exhibit Exhibit 4, # 5 Exhibit Exhibit 5, # 6 Exhibit Exhibit 6, # 7 Exhibit Exhibit 7, # 8 Exhibit Exhibit 8, # 9 Exhibit Exhibit 9, # 10 Exhibit Exhibit 10, # 11 Exhibit Exhibit 11)(Heinrich, Alan) (Entered: 08/13/2018)

Main Doc

Declaration

115

Dec 3, 2018

SEALED DECLARATION IN SUPPORT OF APPLICATION to file document (Reply in Support of Motion to Dismiss and Exhibits J-M) under seal 114 filed by Defendant Kite Pharma, Inc.. (Attachments: # 1 Unredacted Document Reply in Support of Motion to Dismiss, # 2 Unredacted Document Exhibit J, # 3 Unredacted Document Exhibit K, # 4 Unredacted Document Exhibit L, # 5 Unredacted Document Exhibit M)(Lawton, Adam) (Entered: 12/03/2018)

Main Doc

117

Jan 4, 2019

STIPULATION to AMEND Protective Order 75 filed by Defendant Kite Pharma, Inc.. (Attachments: # 1 Amended Protective Order, # 2 Proposed Order)(Lawton, Adam) (Entered: 01/04/2019)

118

Jan 7, 2019

ORDER GRANTING AMENDED PROTECTIVE ORDER by Magistrate Judge Rozella A. Oliver, re Stipulation to Amend Protective Order 117 (dml) (Entered: 01/07/2019)

119

Jan 7, 2019

AMENDED PROTECTIVE ORDER by Magistrate Judge Rozella A. Oliver, re Order Granting 118 (dml) (Entered: 01/07/2019)

122

Jan 24, 2019

Joint STIPULATION to Extend Discovery Cut-Off Date to March 29, 2019 filed by Plaintiffs Juno Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute for Cancer Research. (Attachments: # 1 Proposed Order)(Heinrich, Alan) (Entered: 01/24/2019)

Main Doc

SOURCE

https://www.courtlistener.com/docket/6175992/juno-therapeutics-inc-v-kite-pharma-inc/

Other related sources

35 U.S.C. 271 – Infringement of patent

Other related articles published in this Online Open Access Scientific Journal, include the following:

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/10/04/economic-potential-of-a-drug-invention-prof-zelig-eshhar-weitzman-institute-registered-the-patent-versus-a-cancer-drug-in-clinical-trials-car-t-as-a-case-in-point-developed-by-kite-pharma-unde/

 

Read Full Post »


Newly Elect President of Technion, Professor Uri Sivan: Key Contributions to Scientific Innovations

 

Reporter: Aviva Lev-Ari, PhD, RN

 

February 7, 2019
By: Office of the Technion Spokesperson

The Technion Council, headed by Mr. Gideon Frank, has elected Professor Uri Sivan of the Faculty of Physics as the next president of Technion. The Council’s decision was based on the recommendation of the Search Committee for the Technion President and received sweeping support from the Academic Assembly. The appointment is subject to the final approval of the International Board of Governors, which is set to convene in June.

Professor Uri Sivan

Prof. Sivan will commence his term as President of Technion on October 1 2019, and will replace the outgoing President Prof. Peretz Lavie, who will complete his term after a decade in office.

Prof. Sivan, 64, a resident of Haifa, is married and the father of three. He served as a pilot in the Israeli Air Force. He has a BSc in Physics and Mathematics, an MSc and PhD in Physics, all with honors from Tel Aviv University.

In 1991, after three years at IBM’s T. J. Watson Research Center in New York, Prof. Sivan joined the Faculty of Physics at Technion.

SOURCE

https://ats.org/news/professor-uri-sivan-elected-new-president-of-the-technion/

 

Key Contributions to Scientific Innovations

  • His research has covered a wide range of fields including quantum mesoscopic physics and the harnessing of molecular and cellular biology for the self-assembly of miniature electronic devices. Prof. Sivan, along with colleagues Profs. Erez Braun and Yoav Eichen, demonstrated for the first time how to harness molecular recognition by DNA molecules for wiring an electric circuit. This study gained considerable resonance and helped pave the way for a new field in nanotechnology using the self-assembly properties of biological molecules to construct miniature engineering systems.
  • His research has focused on the way water orders next to molecules and the effect of this ordering on inter-molecular interactions in biologically relevant solutions. Within this framework, Prof. Sivan’s group designs and builds unique, ultra-high-resolution atomic force microscopes.
  • His research has led to patents and industrial applications. Recently, an Israeli start-up company was established in the field of single cell analysis for cancer diagnostics, based on the technology developed in Prof. Sivan’s lab.
  •  Prof. Sivan is the founding director of the Russell Berrie Nanotechnology Institute (RBNI), which he headed between 2005 and 2010.  RBNI has led the scientific revolution in nanotechnology at Technion and has placed the university at the forefront of global research in the field. RBNI made headlines when Prof. Sivan and Dr. Ohad Zohar engraved the entire Hebrew Bible onto a tiny silicon chip. The Nano Bible was written as part of an educational program developed by the Institute to increase young people’s interest in science and especially in nanotechnology. In 2009, President Shimon Peres presented the Nano Bible to Pope Benedict XVI during his official visit to Israel. Today, there are three copies of the chip worldwide: at the Vatican Library, the Smithsonian Museum in Washington D.C., and the Israel Museum in Jerusalem. The establishment of RBNI spearheaded the development of Israel’s national nanotechnology program, and together with centers established in other Israeli universities, has positioned the country as a world leader in nanotechnology.

APPOINTMENTS

Recently, Prof. Sivan was appointed to head the National Advisory Committee in Quantum Science and Technology of the Council for Higher Education’s Planning and Budgeting Committee (PBC). The committee outlined the national quantum academic program, which was adopted and launched last year.

Prof. Sivan has served as a member of the Israeli National Committee for Research and Development (MOLMOP) and the Scientific Advisory Committee of the Batsheva de Rothschild Foundation. He currently serves on the Advisory Committee of the Maof Fellowships Committee for advancing Arab faculty and is a member of the Israeli Wolfson Foundation Advisory Board.

AWARDS

Prof. Sivan is a renowned lecturer in Israel and abroad. He was awarded with numerous prizes including

  • the Mifal Hapais Landau Prize for the Sciences and Research,
  • the Rothschild Foundation Bruno Prize,
  • the Israel Academy of Sciences Bergmann Prize,
  • the Technion’s Hershel Rich Innovation Award, and
  • the Taub Award for Excellence in Research.

 

SOURCE

https://ats.org/news/professor-uri-sivan-elected-new-president-of-the-technion/

Read Full Post »

Older Posts »